Figure 5.

Evaluation of the immunotherapeutic potential of the anti-PSCA IgG4-TM in experimental mice. Immunodeficient NXG mice were subcutaneously injected with PC3-PSCA/PSMA Luc+ alone or in combination with UniCAR T cells in the absence or presence of the anti-PSCA IgG4-TM. (A) Luminescence images for each mouse after day 0, day 1, and day 2 are shown. (B) Quantitative analysis of luminescence signals. For each mouse, net intensities (P/s/mm²) were normalized to net intensities measured at day 0. Mean luminescence net intensities ± SEM for five mice per group are shown (* p < 0.05, ** p < 0.01, compared to the control group “Tumor + UniCAR T”, Student’s t-test).